review Open AccessTop 1% cited
Treatment of Multiple Sclerosis: A Review
The American Journal of Medicine · 2020 · Vol. 133(12) · pp. 1380–1390.e2
Stephen L. Hauser✉(University of California, San Francisco)Bruce Cree(University of California, San Francisco)
Multiple Sclerosis Research StudiesPeripheral Neuropathies and DisordersSARS-CoV-2 and COVID-19 ResearchMedicineMultiple sclerosisTolerabilityDiseaseIntensive care medicineDemyelinating DisorderDemyelinating diseasePediatricsImmunologyAlternative medicine
MeSH terms
Antibodies, MonoclonalHumansImmunosuppressive AgentsMultiple SclerosisPhysical Therapy Modalities
Citations
901
FWCI
57.81
field-weighted impact
References
83
Percentile
100%
vs. same field & year
Citations per year
References
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
Brain · 2011 · 1,153 citations
Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis
Neurology · 1995 · 1,892 citations
Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity
Neurology · 2014 · 1,238 citations
Defining the clinical course of multiple sclerosis
Neurology · 2014 · 3,048 citations
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Brain · 2009 · 1,411 citations
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Annals of Neurology · 1996 · 2,445 citations
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
The Lancet Neurology · 2017 · 7,702 citations
Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis
Frontiers in Immunology · 2019 · 633 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.